ALBACOVIDIOL Study: Effect of Calcifediol Treatment on Mortality in Patients Hospitalized for COVID-19: A Retrospective Analysis
Nutrients · 2025
DOI: 10.3390/nu17121968 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Nutrients, 2025. Verfasst von José Antonio Blázquez-Cabrera und 5 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Department, Complejo Hospitalario Universitario de Albacete, 02008 Albacete, Spain. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Drug Treatment, Calcifediol. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Complejo Hospitalario Universitario de Albacete, Complejo Hospitalario Universitario de Albacete, Albacete, Spain.
Abstract (Originalsprache)
Background
Immunomodulatory treatments targeting excessive host immune responses favorably shifting the course of COVID-19. High doses of calcifediol may reduce the mortality of this infection.
Objective
To evaluate how a high dose of calcifediol modifies the risk of death in patients hospitalized with COVID-19 during the first outbreaks.
Design
A retrospective, observational study to evaluate the relationship between treatment with calcifediol and the risk of death in patients hospitalized with COVID-19 at the “Complejo Hospitalario Universitario de Albacete” (CHUA), Spain, during the months of January to March 2021. Patients were treated with corticosteroids, and some patients also received baricitinib and/or high doses of calcifediol, according to CHUA’s therapeutic protocol 2021 for COVID-19. The primary outcome measure was mortality according to calcifediol treatment.
Results
A total of 230 patients were included. 25(OH)D levels were measured on admission in 148 patients, showing a high prevalence of vitamin D deficiency [median 25(OH)D: 17.5 ng/mL]. Thirty-four (23%) had severe deficiency (25(OH)D ≤ 10 ng/mL). In the 119 patients (51.7%) who received in-hospital treatment with a high dose of calcifediol, the mortality rate was 12.6% (15 cases, 95% confidence interval [CI], 7.8–19.8%), while in 111 patients who did not receive treatment with calcifediol, the death rate was 23.4% (26 cases, 95% CI: 16.5–32.1%; p = 0.039). The odds ratio (OR) in treated vs. untreated patients was 0.47 (95% CI: 0.23–0.95). Among the patients admitted with severe deficiency, 16 received treatment with calcifediol, with a mortality rate of 0.0% (0 cases, 95% CI: 0.0–19.4%), while in the 18 not treated with calcifediol, a death rate of 38.9% was observed (7 cases, 95% CI: 20.3–61.4%; p = 0.008). The mortality rate was lower in patients treated with the combination of calcifediol and corticosteroids vs. those treated with corticosteroids alone (p = 0.038) and vs. those treated with corticosteroids and baricitinib (p = 0.033).
Conclusions
In the ALBACOVIDIOL study, calcifediol treatment was associated with a lower observed mortality rate in hospitalized patients with COVID-19 treated with corticosteroids (with or without baricitinib), especially in those with severe vitamin D deficiency. Causality cannot be inferred due to the retrospective study design. (Public database: ClinicalTrials.gov, NCT05819918).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Internal Medicine Department, Complejo Hospitalario Universitario de Albacete, 02008 Albacete, Spain.
- Clinical Biochemistry Department, Complejo Hospitalario Universitario de Albacete, 02008 Albacete, Spain.
- Clinical and Experimental Endocrinology, Department of Chronic Diseases and Metabolism, KU Leuven, Herestraat, 3000 Leuven, Belgium.
- Unidad de Gestión Clínica de Endocrinología y Nutrición-GC17, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía, 14004 Córdoba, Spain.
- CIBER de Fragilidad y Envejecimiento Saludable (CIBERFES), 14004 Córdoba, Spain.
- Departamento de Enfermería, Farmacología y Fisioterapia, Universidad de Córdoba, 14004 Córdoba, Spain.
ORCID-Profile: José Antonio Blázquez-Cabrera, Javier Torres-Hernández, Antonio Casado-Díaz
Förderung
- Complejo Hospitalario Universitario de Albacete
- Complejo Hospitalario Universitario de Albacete, Albacete, Spain
Zitieren
APA
Blázquez-Cabrera, J. A., Torres-Hernández, J., Bouillon, R., Casado-Díaz, A., Quesada-Gomez, J. M., & Navarro-Casado, L. (2025). ALBACOVIDIOL Study: Effect of Calcifediol Treatment on Mortality in Patients Hospitalized for COVID-19: A Retrospective Analysis. Nutrients. https://doi.org/10.3390/nu17121968
Vancouver
Blázquez-Cabrera JA, Torres-Hernández J, Bouillon R, Casado-Díaz A, Quesada-Gomez JM, Navarro-Casado L. ALBACOVIDIOL Study: Effect of Calcifediol Treatment on Mortality in Patients Hospitalized for COVID-19: A Retrospective Analysis. Nutrients. 2025. doi:10.3390/nu17121968
BibTeX
@article{BlzquezCabrera2025,
author = {Blázquez-Cabrera, José Antonio and Torres-Hernández, Javier and Bouillon, Roger and Casado-Díaz, Antonio and Quesada-Gomez, José Manuel and Navarro-Casado, Laura},
title = {ALBACOVIDIOL Study: Effect of Calcifediol Treatment on Mortality in Patients Hospitalized for COVID-19: A Retrospective Analysis},
journal = {Nutrients},
year = {2025},
doi = {10.3390/nu17121968}
}
EUVIMED